DRD1 and schizophrenia: Indeed, rescue of MK-801-induced vigilance deficits and PCP-induced disinhibition by a dopamine D1 receptor (DRD1) agonist [61,62] aligns with previous evidence that such treatment may enhance cognition in schizophrenia [63].